Homology Medicines Presents Data Showing Single Dose HMI-102 Resulted in Long-Term Correction of PKU, Including Reduction of Phe and Increased Brain Neurotransmitters in Murine Model
Homology Medicines, Inc. (FIXX)
Last homology medicines, inc. earnings: 3/12 04:10 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
- Phase 1/2 pheNIX Study of Gene Therapy Candidate HMI-102 is Underway and Initial Clinical Data is Anticipated by Year End - BEDFORD, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of data highlighting the ability of a single administration of HMI-102, the Company’s lead AAVHSC15 gene therapy candidate for the treatment of phenylketonuria (PKU) in adults, to achieve long-term correction of PKU in PAHenu2 mice on a normal diet. These data, presented in an oral session at the European Society of Human Genetics Conference (ESHG), also demonstrated restoration of key neurotransmitters in the brain to normal levels. PKU is an inborn error of metabolism caused by a mutation in the PAH gene that results in a potentially toxic buildup of phenylalanine (Phe), an essential amino acid derived primarily from dietary protein. Homology recently announced the initiation of the pheNIX study, a Phase 1
Show less
Read more
Impact Snapshot
Event Time:
FIXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FIXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FIXX alerts
High impacting Homology Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
FIXX
News
- Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million [Yahoo! Finance]Yahoo! Finance
- Homology Medicines Declares Distribution to Common StockholdersGlobeNewswire
- Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law FirmGlobeNewswire
- HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXBusiness Wire
- Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases [Yahoo! Finance]Yahoo! Finance
FIXX
Earnings
- 11/14/23 - Miss
FIXX
Sec Filings
- 3/27/24 - Form 8-K
- 3/22/24 - Form 8-K/A
- 3/20/24 - Form 8-K
- FIXX's page on the SEC website